Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tyra Biosciences SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company developing FGFR-focused precision medicines. Recent 8-K reports cover operating results, clinical-program updates for TYRA-300/dabogratinib, officer and board appointments, and capital actions under a registered at-the-market offering program.
Proxy materials describe annual meeting voting matters, board structure and corporate-governance procedures. Registration-linked disclosures and material-event reports also identify TYRA common stock, equity issuance activity, and the company’s use of SEC exhibits for press releases and other official corporate records.
TYRA Biosciences, Inc. received an amended Schedule 13G filing reporting the ownership of a Nextech-managed investment vehicle and related parties. Nextech VI Oncology SCSp beneficially owns 3,553,585 shares of TYRA common stock as of June 30, 2026, representing 6.0% of the class, based on 59,470,381 shares outstanding as of May 8, 2026. Nextech VI GP S.a. r.l. is the sole general partner of Nextech VI Oncology SCSp, and Ian Charoub, Costas Constantinides, and Rocco Sgobbo serve on the GP’s board of managers, with power to direct voting and disposition of these shares. The reporting persons expressly disclaim status as a group for ownership reporting purposes.
Tyra Biosciences, Inc. is the subject of an Amendment No. 2 to a Schedule 13G/A filed by a group of Farallon investment entities and individuals. The reporting group, led by Farallon Capital Management, L.L.C. as investment manager, reports beneficial ownership of 6,000 Shares of Tyra’s common stock (CUSIP 90240B106), representing 0% of the class as of June 30, 2026.
The Shares are held across a series of investment partnerships referred to as the Farallon Funds, for which Farallon Capital Management, L.L.C. acts as investment manager. Item 5 indicates the reporting persons now own 5 percent or less of Tyra’s outstanding common stock. The Farallon Funds have the right to receive dividends and sale proceeds from these securities. Multiple Farallon managing members and senior managing members are included as individual reporting persons, with citizenship and organizational details specified.
The issuer of common stock trading under the symbol TYRA is updating its existing at-the-market equity program. An amendment to the sales agreement with TD Securities (USA) LLC (TD Cowen) permits additional issuances of common stock, par value $0.0001 per share, under an at-the-market offering.
The original sales agreement and related prospectus covered up to a maximum aggregate offering price of $150,000,000, all of which has been sold. After giving effect to this prospectus supplement and the amended sales agreement, the issuer may offer and sell up to an aggregate offering price of $250,000,000 of common stock. The common stock is listed on the Nasdaq Global Select Market, where the last reported sale price was $32.04 per share on August 3, 2026.
Tyra Biosciences, Inc., a clinical-stage FGFR-focused biotech, reports continued operating losses as it advances its pipeline. For the three months ended June 30, 2026, net loss was $45.6 million on operating expenses of $49.0 million, including research and development expense of $39.2 million and general and administrative expense of $9.8 million. For the first half of 2026, net loss was $84.9 million on research and development expense of $72.7 million and general and administrative expense of $18.3 million, with no product revenue.
The company highlights progress across oral dabogratinib Phase 2 trials in LG-UTUC (SURF303), IR NMIBC (SURF302) and achondroplasia (BEACH301), plus TYRA-430 in FGF19+ HCC and TYRA-200 in FGFR2-driven ICC. Initial SURF302 results are expected in September 2026, with first BEACH301 and SURF303 readouts anticipated in 2027.
Liquidity remains a key focus: as of June 30, 2026, Tyra held $353.9 million in cash, cash equivalents and marketable securities. It raised $147.9 million in Q1 2026 via an at-the-market offering and subsequently amended that program to permit additional sales of up to $250.0 million, and management believes existing resources will fund operations into the second half of 2028.
Tyra Biosciences, Inc. reported second quarter 2026 results as a clinical-stage biotechnology company focused on FGFR biology. For the quarter ended June 30, 2026, net loss was $45.6 million, with research and development expenses of $39.2 million and general and administrative expenses of $9.8 million. Net loss per share was $0.69 basic and diluted. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $353.9 million.
Management highlighted its “dabogratinib 3x3” strategy, advancing three Phase 2 trials (SURF303 in LG-UTUC, SURF302 in IR NMIBC and BEACH301 in achondroplasia), with initial SURF302 data expected in September 2026 and BEACH301 safety cohort data by end of first quarter 2027. The safety sentinel cohort in BEACH301 has cleared four dose levels without notable safety events, and a fifth dose level has been opened. Tyra appointed Jonathan Day as Executive Vice President, Clinical Development for skeletal dysplasia conditions and amended its at-the-market equity sales agreement, enabling up to an additional $250.0 million in common stock sales. Current cash resources are expected to fund planned operations into the second half of 2028.
BlackRock, Inc. reports a passive ownership stake in TYRA Biosciences, Inc. common stock. BlackRock and certain of its business units beneficially own 2,976,228 shares of TYRA common stock, representing 5.00% of the outstanding class. Of these shares, BlackRock has sole voting power over 2,924,904 shares and sole dispositive power over all 2,976,228 shares, with no shared voting or dispositive power reported. Various underlying clients have economic rights to dividends and sale proceeds, but no single client holds more than five percent of TYRA’s total outstanding common shares.
NEXTECH VI ONCOLOGY SCSP reported sales of TYRA common stock under a Rule 144 notice. The excerpt lists four dispositions in June 2026 with specific trade dates, share quantities, and gross proceeds for each trade. The broker listed is Merrill Lynch.
Tyra Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 28, 2026. Stockholders elected three directors: Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More. Each nominee received over 41 million votes in favor, with 8,377,977 broker non-votes recorded on each director item.
Stockholders also approved another meeting proposal with 53,092,820 votes for, 1,316 against, and 3,246 abstentions, and no broker non-votes.
Tyra Biosciences, Inc. reported a Form 4 showing a grant of stock options to non-employee director Jake Simson, held for the benefit of RA Capital-managed entities. The award covers 13,160 options for common stock at an exercise price of $32.68 per share and was received for no cash cost.
The options were granted under the company’s Non-Employee Director Compensation Program. One-twelfth of the award vests monthly after May 28, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within a year, subject to Mr. Simson’s continued service.
Under Mr. Simson’s arrangement with RA Capital Management, any net cash or stock from exercising these options must be turned over to the adviser for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund, and a separately managed account, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Tyra Biosciences director Rehan Verjee received a stock option grant covering 13,160 shares of common stock, with an exercise price of $32.68 per share. The option was granted under the Non-Employee Director Compensation Program and vests in 12 equal monthly installments after May 28, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within a year and service continues. Following this award, Verjee holds options for 13,160 shares.